title: Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.
abstract: The purpose of this study was to evaluate the antitumor activity of vinorelbine and oral estramustine phosphate in patients with metastatic, hormone-refractory prostate cancer. We evaluated the activity of this association using the following schedule: estramustine phosphate 600 mg/m2/day orally days 1-42 and vinorelbine 25 mg/m1 days 1, 8, 22, 29 cycles repeated every 56 days. Twenty-five patients were included in the study, 24 being evaluable for response and 25 for toxicity. Out of 5 patients with measurable disease, none had an objective response. Of the 24 assessable patients with bone metastases, 9 patients had a > or = 65% decline in pretreatment prostate-specific antigen (PSA) level, stable disease was observed in 10 and 5 patients progressed. Toxicities were minimal. Anemia was observed in 5 patients, alopecia in 4 and nausea and vomiting was observed in 6 patients. Anorexia and weight loss of more than 10% were observed in 2 patients. This combination is active and well tolerated in hormone-resistant prostate cancer. These results support the therapeutic strategy of combining agents that impair microtubule function.
authors.affiliation: Uro-Oncology Unit, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Spain. 90604@imas.imim.es
authors.forename: J
authors.initials: J
authors.lastname: Carles
authors.forename: M
authors.initials: M
authors.lastname: Domenech
authors.forename: A
authors.initials: A
authors.lastname: Gelabert-Mas
authors.forename: M
authors.initials: M
authors.lastname: Nogue
authors.forename: J M
authors.initials: JM
authors.lastname: Tabernero
authors.forename: A
authors.initials: A
authors.lastname: Arcusa
authors.forename: I
authors.initials: I
authors.lastname: Guasch
authors.forename: A
authors.initials: A
authors.lastname: Miguel
authors.forename: J J
authors.initials: JJ
authors.lastname: Ballesteros
authors.forename: X
authors.initials: X
authors.lastname: Fabregat
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D004961:Estramustine; D014747:Vinblastine; D000077235:Vinorelbine